Skip to main content
Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.980
-0.020 (-1.00%)
Nov 20, 2024, 4:00 PM EST - Market closed

Inhibikase Therapeutics Revenue

Inhibikase Therapeutics had revenue of $1.00 in the twelve months ending September 30, 2024, down -100.00% year-over-year. In the year 2023, Inhibikase Therapeutics had annual revenue of $260.50K with 111.03% growth.

Revenue (ttm)
$1.00
Revenue Growth
-100.00%
P/S Ratio
n/a
Revenue / Employee
$0
Employees
9
Market Cap
133.04M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023260.50K137.06K111.03%
Dec 31, 2022123.44K-2.98M-96.02%
Dec 31, 20213.10M2.40M343.92%
Dec 31, 2020698.47K-424.27K-37.79%
Dec 31, 20191.12M-2.92M-72.22%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Puma Biotechnology 243.57M
Innate Pharma 36.20M
Avalo Therapeutics 820.00K
Cardiff Oncology 688.00K
Zentek 29.13K
Revenue Rankings

IKT News

More News